Your browser doesn't support javascript.
loading
Mycophenolate mofetil as an immunomodulator in refractory noninfectious uveitis.
Rodriguez, Ever Ernesto Caso; Sakata, Viviane Mayumi; Cavalcanti, Daniel Cesar Torres Melo; Zaghetto, Juliana Marques; Olivalves, Edilberto; Hirata, Carlos Eduardo; Yamamoto, Joyce Hisae.
Afiliação
  • Rodriguez EE; Clínica Oftalmológica, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brasil.
  • Sakata VM; Clínica Oftalmológica, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brasil.
  • Cavalcanti DC; Clínica Oftalmológica, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brasil.
  • Zaghetto JM; Clínica Oftalmológica, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brasil.
  • Olivalves E; Clínica Oftalmológica, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brasil.
  • Hirata CE; Clínica Oftalmológica, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brasil.
  • Yamamoto JH; Clínica Oftalmológica, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brasil.
Arq Bras Oftalmol ; 79(6): 369-372, 2016.
Article em En | MEDLINE | ID: mdl-28076562
PURPOSE:: To evaluate the efficacy and tolerance of mycophenolate mofetil (MMF) for the treatment of noninfectious uveitis using the methods advocated by the Standardization of Uveitis Nomenclature (SUN) Working Group and to compare this with other studies of immunosuppression in ocular inflammation. METHODS:: Retrospective case series. Patients with noninfectious uveitis, followed at a tertiary Uveitis Service in São Paulo, Brazil, from 2007 to 2014 and receiving oral MMF for a minimum of 6 months, were retrospectively reviewed. After reaching an optimal dose of MMF, patients were evaluated after 6 (T6), 12 (T12), and 24 months (T24). The optimal dose varied for each patient (medium 2.2 g/day, range 1.0-3.0 g/day). The main outcome measures were: 1) success on achieving complete control of inflammation in both eyes and/or oral prednisone dosage reduction to ≤10 mg per day, and 2) the length of time required to reduce oral prednisone to ≤10 mg/day, partial control of ocular inflammation, and side effects. RESULTS:: In a cohort of 16 patients with refractory noninfectious uveitis, 67% reached the ideal prednisone dose after 1 year of MMF treatment and 83% after 2 years of MMF treatment. Complete or partial inflammation control was achieved in 43.7% at T12. Two patients (14%) had disease remission after 4.7 years of MMF treatment. Adverse effects were gastrointestinal disturbances, infection, insomnia, and liver function abnormalities at a rate of 0.03 patient-year each. CONCLUSIONS:: This small retrospective case series is consistent with the literature concerning the high efficacy and moderate tolerability of MMF in noninfectious uveitis. Observation of patients should be continued for at least 1 year to clearly determine MMF efficacy.
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Uveíte / Imunossupressores / Ácido Micofenólico Tipo de estudo: Observational_studies Limite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Arq Bras Oftalmol Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Brasil País de publicação: Brasil
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Uveíte / Imunossupressores / Ácido Micofenólico Tipo de estudo: Observational_studies Limite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Arq Bras Oftalmol Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Brasil País de publicação: Brasil